Head-to-head evidence
Alogliptin vs Anagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Alogliptin · Nesina
Marketed by Takeda Pharmaceutical Company
NCT00286429 · Phase 3 · completed
The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.
Next expected readout: December 2026 · NCT07093476 (registry estimate)
Anagliptin · Suiny
Marketed by JW Pharmaceutical
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Anagliptin's landscape